{"id":"https://openalex.org/W4211168024","doi":"https://doi.org/10.1038/d41573-022-00030-4","title":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","display_name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","alternate_titles":[],"publication_year":2022,"publication_date":"2022-02-10","ids":{"openalex":"https://openalex.org/W4211168024","doi":"https://doi.org/10.1038/d41573-022-00030-4","pmid":"https://pubmed.ncbi.nlm.nih.gov/35145263"},"language":"en","primary_location":{"id":"doi:10.1038/d41573-022-00030-4","doi":"https://doi.org/10.1038/d41573-022-00030-4","is_oa":false,"landing_page_url":"https://doi.org/10.1038/d41573-022-00030-4","pdf_url":null,"source":{"id":"https://openalex.org/S186543748","display_name":"Nature Reviews Drug Discovery","issn_l":"1474-1776","issn":["1474-1776","1474-1784"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Reviews Drug Discovery","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4211168024"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088968544","display_name":"Samik Upadhaya","orcid":"https://orcid.org/0009-0005-0932-2588","observed_orcids":["https://orcid.org/0009-0005-0932-2588"]},"institutions":[{"id":"https://openalex.org/I169071179","display_name":"Cancer Research Institute","ror":"https://ror.org/02f3xk561","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I169071179"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Samik Upadhaya","raw_affiliation_strings":["Cancer Research Institute, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research Institute, New York, NY, USA","institution_ids":["https://openalex.org/I169071179"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079464241","display_name":"Svetoslav T. Neftelinov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svetoslav T. Neftelinov","raw_affiliation_strings":["IQVIA, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IQVIA, Durham, NC, USA","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063597274","display_name":"Jeffrey P. Hodge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Hodge","raw_affiliation_strings":["IQVIA, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IQVIA, Durham, NC, USA","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074498310","display_name":"Jay Campbell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169071179","display_name":"Cancer Research Institute","ror":"https://ror.org/02f3xk561","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I169071179"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Campbell","raw_affiliation_strings":["Cancer Research Institute, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research Institute, New York, NY, USA","institution_ids":["https://openalex.org/I169071179"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5088968544"],"corresponding_institution_ids":["https://openalex.org/I169071179"],"apc_list":null,"apc_paid":null,"fwci":20.6666,"has_fulltext":false,"cited_by_count":224,"citation_normalized_percentile":{"value":0.99676241,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"21","issue":"7","first_page":"482","last_page":"483"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.9760000109672546},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9769999980926514},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9639999866485596},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/clinical-trial-design","display_name":"clinical trial design","score":0.8980000019073486},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6510000228881836},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.4259999990463257},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.48899999260902405}],"concepts":[{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6044584512710571},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.42685019969940186},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42621922492980957},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21843275427818298},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.16663077473640442},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.07285428047180176}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1038/d41573-022-00030-4","doi":"https://doi.org/10.1038/d41573-022-00030-4","is_oa":false,"landing_page_url":"https://doi.org/10.1038/d41573-022-00030-4","pdf_url":null,"source":{"id":"https://openalex.org/S186543748","display_name":"Nature Reviews Drug Discovery","issn_l":"1474-1776","issn":["1474-1776","1474-1784"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Reviews Drug Discovery","raw_type":"journal-article"},{"id":"pmid:35145263","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35145263","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature reviews. Drug discovery","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8048999905586243}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388141584","https://openalex.org/W3105655002","https://openalex.org/W2984238186","https://openalex.org/W4206339561","https://openalex.org/W4365510442","https://openalex.org/W2066387105","https://openalex.org/W2902968854","https://openalex.org/W2983894393","https://openalex.org/W4394697931","https://openalex.org/W4205599925"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4211168024","counts_by_year":[{"year":2026,"cited_by_count":24},{"year":2025,"cited_by_count":55},{"year":2024,"cited_by_count":62},{"year":2023,"cited_by_count":45},{"year":2022,"cited_by_count":37}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-02-13T00:00:00"}
